Showing results (381-390 of 1,831) with videos related to

Sort By:
Pageof 184
ESMO Open|January 28, 2024
Sexual quality of life of adolescents and young adult breast cancer survivorsN J M C Vrancken Peeters, C Vlooswijk, R M Bijlsma, et al.
ESMO Open|July 30, 2023
Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumorsK Kairemo, M A Gouda, L Buschhorn, et al.
ESMO Open|July 29, 2023
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trialM Ferreiro-Pantín, U Anido-Herranz, Y Z Betancor, et al.
ESMO Open|August 10, 2023
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in JapanY Kagawa, E Shinozaki, R Okude, et al.
ESMO Open|March 20, 2026
Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and AsiaH S Rugo, S M Tolaney, J Cortés, et al.
ESMO Open|March 27, 2026
A machine learning assay to predict disease recurrence in hormone receptor-positive breast cancerL Boscolo Bielo, D Trapani, P Razavi, et al.
ESMO Open|April 10, 2026
New prognostic and predictive scoring systems for colorectal cancer liver metastasesF Salvà, S Pérez Fernandez, C Dopazo, et al.
ESMO Open|April 10, 2026
Association of comprehensive inflammatory-metabolic status and perioperative outcomes in gastric cancer: insights from four randomized controlled trialsL-K Zhang, Z-X Shang-Guan, H-L Zheng, et al.
ESMO Open|April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trialG Curigliano, J O'Shaughnessy, F-C Bidard, et al.
ESMO Open|April 19, 2024
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutationsJ Rodon, E Rodriguez, M L Maitland, et al.
Pageof 184